Other Events ·
Evaxion A/S will present three-year clinical efficacy data for its personalized cancer vaccine candidate, EVX-01, at…
EVAXEvaxion A/S
Evaxion A/S will present three-year clinical efficacy data for its personalized cancer vaccine candidate, EVX-01, at the ESMO Congress 2026 in Madrid, Spain, scheduled for October 24, 2026. The data stems from a phase 2 trial evaluating EVX-01 in patients with advanced melanoma, including a one-year extension where patients received the vaccine as a stand-alone therapy. Previous two-year data showed a 75% Objective Response Rate and a 92% response durability at the two-year follow-up. The presentation aims to provide insights into treatment effects and immune response durability. Evaxion A/S is a TechBio company that develops personalized and off-the-shelf cancer and infectious disease vaccines using its AI-Immunology platform.